These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 19594773)
1. The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. Badowski M; Gurk-Turner C; Cangro C; Weir M; Philosophe B; Klassen D; Haririan A Clin Transplant; 2009; 23(6):930-7. PubMed ID: 19594773 [TBL] [Abstract][Full Text] [Related]
2. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy. El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298 [TBL] [Abstract][Full Text] [Related]
3. Immunosuppression in live-related donor renal transplantation. Iman A; Rao M; Juneja R; Jacob CK Natl Med J India; 2001; 14(2):75-80. PubMed ID: 11396322 [TBL] [Abstract][Full Text] [Related]
4. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. Morris JA; Hanson JE; Steffen BJ; Chu AH; Chi-Burris KS; Gotz VP; Gordon RD Clin Transplant; 2005 Jun; 19(3):340-5. PubMed ID: 15877795 [TBL] [Abstract][Full Text] [Related]
5. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508 [TBL] [Abstract][Full Text] [Related]
6. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival. McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381 [TBL] [Abstract][Full Text] [Related]
17. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Luan FL; Schaubel DE; Zhang H; Jia X; Pelletier SJ; Port FK; Magee JC; Sung RS Transplantation; 2008 Jun; 85(11):1601-6. PubMed ID: 18551066 [TBL] [Abstract][Full Text] [Related]
18. The impact of age on patient tolerance of mycophenolate following kidney transplantation. Rennie TJW; Petrie M; Metcalfe W; Walbaum D; Joss N; Barton E; Marson L; Clancy MJ; Henderson L; Traynor JP; Geddes CG; Phelan PJ Nephrology (Carlton); 2020 Jul; 25(7):566-574. PubMed ID: 32323461 [TBL] [Abstract][Full Text] [Related]
19. De novo noncutaneous malignancies after kidney transplantation are associated with an increased risk of graft failure: results from a time-dependent analysis on 672 patients. Cena T; Musetti C; Quaglia M; Magnani C; Stratta P; Bagnardi V; Cantaluppi V Transpl Int; 2016 Oct; 29(10):1085-93. PubMed ID: 27343849 [TBL] [Abstract][Full Text] [Related]
20. Excessive immunosuppression in kidney transplant patients: prevalence and outcomes. Sanders-Pinheiro H; da Silveira ST; Carminatti M; Braga LS; Marsicano EO; Magalhães GL; Carvalho LF; Filho GF; Magacho EJ; Colugnati F; Bastos MG Transplant Proc; 2012 Oct; 44(8):2381-3. PubMed ID: 23026599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]